retatrutide phase 2 trial type 2 diabetes weight loss 2024 Retatrutide, a TRIPLE agonist (GLP1, GIP, glucagon), just released results demonstrating 25% in half of people with #obesity. This amount of weight loss has not been accomplished Retatrutide—A Game Changer in Obesity

Endocrinologia, Diabetes y Nutricion, 64 (5), 278280

Lets get to it

Retatrutides effectiveness in both adipose tissue reduction and glycemic control suggests it could be a game-changing therapy for type 2 diabetes and obesity management (McPherson et al., 2023)

Injectables can over-plump or distort facial contours if not done carefully, and surgical options are invasive and irreversible

[2] [3] For many patients with established cardiovascular disease or high cardiovascular risk, SGLT2 inhibitors are preferred before GLP-1 receptor agonists where appropriate

Importantly, these medications carry a boxed warning for risk of thyroid C-cell tumors and are contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN2)